Treatment for eGFR of 24 mL/min/1.73 m²
Start an SGLT2 inhibitor immediately—this is the single most important intervention to reduce mortality and prevent kidney failure in stage 4 CKD. 1
Core Pharmacologic Treatment Algorithm
1. SGLT2 Inhibitor (Highest Priority)
- Initiate regardless of diabetes status with eGFR 24 mL/min/1.73 m² 1
- This carries a 1A recommendation (strongest evidence level) from KDIGO 2024
- Continue even if eGFR drops below 20 mL/min/1.73 m² once started 1
- The reversible eGFR dip after initiation is not a reason to stop 1
- Withhold only during: prolonged fasting, surgery, or critical illness (ketosis risk) 1
2. RAS Inhibitor (ACE-I or ARB)
The decision depends on albuminuria status:
If albuminuria ≥30 mg/g (A2 or A3):
- Start ACE-I or ARB at maximum tolerated dose 1
- Continue even with eGFR <30 mL/min/1.73 m² 1
- Monitor creatinine and potassium within 2-4 weeks 1
- Continue unless creatinine rises >30% within 4 weeks 1
- Manage hyperkalemia with potassium-lowering measures rather than stopping the drug 1
If no albuminuria (A1):
- Consider RAS inhibitor for hypertension or heart failure with reduced ejection fraction 1
3. Nonsteroidal MRA (Finerenone)
Only if:
- Type 2 diabetes present
- eGFR >25 mL/min/1.73 m² (your patient at 24 is just below threshold) 1
- Potassium ≤4.8 mmol/L
- Persistent albuminuria despite maximum RAS inhibitor 1
Critical caveat: At eGFR 24, this patient is at the lower boundary and would need eGFR rechecked—if it's truly <25, hold off on MRA 1
4. GLP-1 Receptor Agonist
If type 2 diabetes present and not at glycemic target:
- Add long-acting GLP-1 RA (prioritize agents with cardiovascular benefits like semaglutide or dulaglutide) 1
- This is in addition to, not instead of, SGLT2 inhibitor 1
Blood Pressure Management
- Target systolic BP: 120 mmHg if tolerated without hypotension 1
- Use standardized office measurement technique
- RAS inhibitor serves dual purpose for BP and kidney protection
Monitoring Requirements
Within 2-4 weeks of starting/adjusting RAS inhibitor:
- Serum creatinine
- Serum potassium
- Blood pressure 1
After starting SGLT2 inhibitor:
- No change in monitoring frequency needed 1
- Expect small reversible eGFR decrease—do not panic and stop the drug 1
If starting MRA (when eGFR >25):
- Potassium at 1 month, then every 4 months 1
Critical Pitfalls to Avoid
Do not withhold SGLT2 inhibitor because eGFR is "too low"—the 2024 KDIGO guidelines explicitly recommend use down to eGFR 20 1
Do not stop RAS inhibitor when eGFR falls below 30—continue unless creatinine rises >30% acutely, symptomatic hypotension, or uncontrolled hyperkalemia 1
Do not discontinue SGLT2 inhibitor for the expected initial eGFR dip 1
Do not reduce RAS inhibitor dose for hyperkalemia before attempting potassium-lowering strategies (dietary restriction, diuretics, potassium binders) 1
Do not use MRA if potassium >4.8 mmol/L or eGFR <25 mL/min/1.73 m² 1
Additional Management Considerations
Nephrology referral is indicated at this stage (eGFR <30 mL/min/1.73 m²) for:
- Preparation for kidney replacement therapy
- Management of CKD complications (anemia, mineral bone disease, metabolic acidosis)
- Consideration of transplant evaluation 2
Avoid nephrotoxins:
- NSAIDs
- Aminoglycosides
- Contrast agents when possible 2
Adjust medication dosing for reduced kidney function (many antibiotics, oral hypoglycemics) 2
Lifestyle modifications:
- Dietary protein restriction to 0.8 g/kg/day 3
- Sodium restriction to 2 g/day 3
- Smoking cessation (reduces progression risk by 9-11%) 4
Evidence Strength
The 2024 KDIGO guidelines 1 represent the most current and authoritative source, incorporating 937 references. The SGLT2 inhibitor recommendation is Grade 1A (strongest possible)—meaning high-quality evidence shows clear benefit for mortality and kidney failure prevention. The evidence is so strong that SGLT2 inhibitors are now recommended regardless of diabetes status, which represents a major shift from previous guidelines 5.